


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re application of:

Catherine GUENTHER et al.

Application No.: 09/883,093

Filed: June 14, 2001

For: Transgenic Mice Containing Nuclear Hormone Receptor Gene Disruptions

Examiner: Unassigned

Art Unit: 1632

Atty. Docket No.: R-126

**PRELIMINARY AMENDMENT**

RECEIVED

NOV 08 2002

TECH CENTER 1600/2900

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to the examination of the above-referenced application and in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed October 2, 2002, entry of the following amendment is respectfully requested:

**In the Drawings**

Please replace Figure 2A in the application with the enclosed new Figure 2A.

**REMARKS**

The amendment to Figure 2A merely adds a sequence identifier to the figure to comply with 37 C.F.R. 1.821(d) and does not introduce new matter. Entry of the foregoing amendment is respectfully requested.

Favorable action on the merits is earnestly solicited.

Date: November 1, 2002

Respectfully submitted,

*Mariette A. Lapiz*  
Mariette A. Lapiz, Reg. No. 44,202

DELTAGEN, INC.  
740 Bay Road  
Redwood City, CA 94063  
(650) 569-5100

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8**

I hereby certify that this correspondence and its listed enclosures is being deposited with the United States Postal Service as First Class Mail, postage paid, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on November 1, 2002  
Name: Deborah A. Mojarro

Signed: *Samojan*

Date: 11/1/02